Jun 23 2012
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
announced today that people with HER2-positive metastatic breast cancer
(mBC) lived significantly longer (overall survival) when treated with
the combination of Perjeta™ (pertuzumab), Herceptin®
(trastuzumab) and docetaxel chemotherapy, compared to Herceptin and
docetaxel chemotherapy alone in the Phase III CLEOPATRA study. These
data will be submitted for presentation at an upcoming medical meeting.
"We are pleased that Perjeta helped people with HER2-positive metastatic
breast cancer live longer and lengthened the time they lived without
their disease worsening," said Hal Barron, M.D., chief medical officer
and head, Global Product Development. "The improvement in survival seen
in the CLEOPATRA study is great news for patients and doctors, and
reinforces our belief that Perjeta will improve the outlook for people
with this devastating disease."
Perjeta is a personalized medicine that targets the HER2 receptor, a
protein found in high quantities on the outside of cancer cells in
HER2-positive cancers. Perjeta is believed to work in a way that is
complementary to Herceptin, as the two medicines target different places
on the HER2 receptor.
The FDA recently approved Perjeta in combination with Herceptin and
docetaxel chemotherapy for the treatment of people with HER2-positive
mBC who have not received prior anti-HER2 therapy or chemotherapy for
metastatic disease, based on the results of the CLEOPATRA study. Roche
has also submitted a Marketing Authorization Application to the European
Medicines Agency (EMA) for Perjeta for people with previously untreated
HER2-positive mBC.
Source: Genentech
How different types of bread impact cancer risk